UNSPSC 51151654: Obidoxime

This classification denotes an anticholinergic agent with the molecular formula C14H16N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N6KNE1QA9O, chemically known as 4,4-bis-(hydroxyiminomethyl)-1,1-oxydimethylen-dipyridinium-kation but generally known as obidoxime, which bears US NIH Compound Identifier 5485192. European Medicines Agency schedules Obidoxime in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14676MIG.

UNSPSC 51151654 Obidoxime, a Commodity code, describes pharmaceutical antidote products that state and local governments procure for emergency medical response and public health initiatives. The recent solicitation activity under this code shows state and local health departments and county emergency services acquiring naloxone and related drug-reversal systems to support overdose response and community health programs, though the code's narrow pharmaceutical focus limits the volume of active procurement.

Seminole County, Florida, posted an IFB (Invitation for Bid) in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The IFB required electronic bid submission through the county's e-Procurement Portal, with a response deadline of July 26, 2023, and included standard compliance requirements such as drug-free workplace certification, E-Verify confirmation, and insurance coverage (workers' compensation, commercial general liability, and professional liability). The contract offered an initial two-year term with a one-year renewal option and included a three-month probationary termination clause. The procurement did not specify set-aside designations for disadvantaged enterprises and was potentially funded through FEMA, which imposed additional compliance obligations under federal environmental and contracting regulations. Beyond this Seminole County opportunity, the source reveals limited recent state and local activity under the obidoxime code, indicating this is a narrow, specialized pharmaceutical procurement category with infrequent solicitation volume.